International Distribution Agreement



 EXHIBIT 10.36 
 INTERNATIONAL DISTRIBUTION AGREEMENT BETWEEN 
 CONOR MEDSYSTEMS IRELAND LTD. 
 AND

 INTERVENTIONAL TECHNOLOGIES LIMITED 
 THIS INTERNATIONAL DISTRIBUTION AGREEMENT (the “Agreement”) is made
and entered into as of April 1, 2006, by and between CONOR MEDSYSTEMS IRELAND LTD., an Irish corporation having its offices at IDA Business and Technology Park, Garrycastle,
Athlone, County Westmeath, Ireland (“Conor”), and INTERVENTIONAL TECHNOLOGIES LIMITED, an Indian corporation having its offices in Mumbai, India 201, Steel House, 2nd Floor 24,
Mahal Industrial Estate, Mahakali Caves Road, Andheri(E) Mumbai-400 093 (the “Distributor”). 
 WITNESSETH:

 WHEREAS, Conor owns certain proprietary drug-eluting stent products and related technology; 
 WHEREAS, Distributor desires an exclusive right to distribute a certain product in India, Pakistan, Bangladesh, Sri Lanka, Kenya,
and Tanzania; 
 NOW, THEREFORE, in consideration of the mutual covenants and conditions herein
contained, and intending to be legally bound hereby, the parties mutually agree as follows: 
 1. PRODUCT AND
TERRITORY. 
 (a) Appointment. Subject to the terms and conditions of this Agreement, Conor hereby
appoints Distributor on an exclusive basis as its sole distributor in the Territory (as defined below) for the sale of the product listed in Exhibit A (the “Product”) during the term of this Agreement. 
 (b) Territory. Conor is appointing Distributor hereunder with respect to the resale of the Product to any purchasers whose
principal place of business is located in India, Pakistan, Bangladesh, Sri Lanka, Kenya, and Tanzania (the “Territory”). 
 (c) Activities outside the Territory. Distributor shall refrain from establishing or maintaining any branch, warehouse or distribution facility for the Product outside of the Territory. Distributor shall not
engage in any advertising or promotional activities relating to the Product directed primarily to customers outside the Territory. Distributor shall not solicit orders from any prospective purchaser with its principal place of business located
outside the Territory. Distributor shall not sell any Product to a purchaser if Distributor knows or has reason to believe that such purchaser intends to remove such Product from the Territory. 
 (d) Requests from outside the Territory. If Distributor receives any order from a prospective purchaser whose principal place of
business is located outside the Territory, Distributor shall immediately refer that order to Conor. Distributor shall not accept any such orders. Distributor may not deliver or tender (or cause to be delivered or tendered) any Product outside of the
Territory. 
  



	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 1. 








 (e) Expansion of Products and Territory. Conor reserves the right, in its sole
discretion, at any time upon thirty (30) days’ prior written notice to Distributor, to expand or reduce in any manner the Product which is covered by this Agreement. Conor also reserves the right, in its sole discretion, at any time upon
thirty (30) days’ prior written notice to Distributor, to expand or reduce in any manner the Territory, as defined in this Agreement. 
 (f) Change of Control of Distributor. In the event of a Change of Control of Distributor, Conor shall have the right to appoint an additional distributor for the Territory, and the distributorship granted to
Distributor in Section 1(a) shall automatically convert from an exclusive appointment to a co-exclusive appointment. For the purpose of this Section 1(f), “Change of Control of Distributor” shall mean (i) any consolidation
or merger of Distributor with or into any other corporation or other entity or person, or any other corporate reorganization, in which the capital stock of Distributor immediately prior to such consolidation, merger or reorganization, represents
less than fifty percent (50%) of the voting power of the surviving entity (or, if the surviving entity is a wholly owned subsidiary, its parent) immediately after such consolidation, merger or reorganization; or (ii) any transaction or
series of related transactions to which Distributor is a party in which more than fifty percent (50%) of Distributor’s voting power is transferred to a third party; or (iii) the consummation of a sale of all or substantially all of
the assets of Distributor in any transaction or series of related transactions, other than a sale of all or substantially all of the assets of Distributor to an entity, more than fifty percent (50%) of the combined voting power of the voting
securities of which are owned by shareholders of Distributor in substantially the same proportions as their ownership of Distributor immediately prior to such sale. 
 2. PRICES AND PAYMENT. 
 (a) Ordering.
Distributor shall order the Product from Conor by submitting a written purchase order identifying the requested delivery date(s) and any export/import information required to enable Conor to fill the order. All orders for the Product are subject
to acceptance by Conor. Conor shall have no liability to Distributor with respect to purchase orders which are not accepted; provided, however, that Conor will not unreasonably reject any purchase order for the Product that meets the requirements of
this Section 2(a) and that does not request any modifications or additions to the Product. 
 (b) Pricing by
Conor. If a purchase order is accepted in accordance with Section 2(a) above, the price for the Product covered by such purchase order shall be in euros in accordance with the Product and Price List set forth in Exhibit A. Conor may from
time to time amend Exhibit A to change those prices, such change being effective immediately upon Distributor’s receipt of notice thereof; provided, however, that no price change shall affect purchase orders offered by Distributor and accepted
by Conor prior to the date such price change becomes effective. 
  



	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 2.









 (c) Pricing by Distributor. Distributor shall be free to establish its own pricing
for the Product sold. Distributor shall notify Conor of its pricing, as in effect from time to time. 
 (d)
Limitations. The ultimate shipment of orders to Distributor shall be subject to the right and ability of Conor to make such sales and obtain required licenses and permits, under all decrees, statutes, rules and regulations of the government of
the United States and agencies thereof presently in effect or which may be in effect hereafter. 
 (e) Distributor
representations. Distributor hereby agrees: (i) to assist Conor in obtaining any required licenses, permits or approvals or complying with any other regulatory requirements in the Territory by providing all reasonably requested support,
including but not limited to supplying such documentation or information as may be requested by Conor; (ii) to comply with such decrees, statutes, rules and regulations of the government of the United States and agencies thereof; (iii) to
maintain the necessary records to comply with such decrees, statutes, rules and regulations; (iv) to not re-export any Product except in compliance with such decrees, statutes, rules and regulations; (v) to not sell, transfer, or otherwise
dispose of the Product in violation of the export laws of the United States; (vi) to translate to English and provide to Conor copies of any submissions made in accordance with this Section 2(e) or Section 30; and (vii) to
indemnify and hold harmless Conor from any and all fines, damages, losses, costs and expenses (including reasonable attorneys’ fees) incurred by Conor as a result of any breach of this subsection or subsection (f) below by Distributor or
any of Distributor’s customers. 
 (f) Export controls. Distributor hereby expressly acknowledges that the
technical data and the direct product thereof are subject to export controls of the United States and agrees that neither the technical data nor the direct product thereof will be transferred, directly or indirectly, to any destination contrary to
the requirements of the law of the United States, including but not limited to the terms of any export license and the terms of Part 774 (re-exports) of the U.S. Export Administration Regulations. Further, Distributor hereby provides its assurance
that it will not participate in any transaction which may involve any commodity or technical data, or the direct product thereof, exported or to be exported from the United States, or in any re-export thereof, or in any other transaction that is
subject to export controls of the United States, if a person denied export privileges from the United States may obtain any benefit from or have any interest in, directly or indirectly, these transactions. 
 (g) Packing and shipment. Unless Distributor requests otherwise, all Product ordered by Distributor shall be packed for shipment
and storage in accordance with Conor’s standard commercial practices. It is Distributor’s obligation to notify Conor of any special packaging requirements (which shall be at Distributor’s expense). Risk of loss and damage to a Product
shall pass to Distributor upon the delivery of such Product to the common carrier designated by Distributor FCA (Incoterms 2000). All claims for non-conforming shipments must be made in writing to Conor within ten (10) days of the passing of
risk of loss and damage, as described above. Any claims not made within such period shall be deemed waived and released. 
  



	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 3.









 (h) Payments. All amounts due and payable with respect to a Product delivered by
Conor in accordance with the preceding subsection shall be paid in full within thirty (30) days after date of invoice covering such Product. All such amounts shall be paid in euros by wire transfer, to such bank or account as Conor may from
time to time designate in writing. Whenever any amount hereunder is due on a Business Day, such amount shall be paid on the next such Business Day. For the purpose of this Agreement, a “Business Day” shall mean a day on which banks in
Dublin, Ireland are open for business. Amounts hereunder shall be considered to be paid as of the day on which funds are received by Conor or into Conor’s account. No part of any amount payable to Conor hereunder may be reduced due to any
counterclaim, set-off, adjustment or other right which Distributor might have against Conor, any other party or otherwise. 
 (i) Letter of Credit. For each and every Distributor purchase order submitted according to Section 2 (a), Distributor shall deliver to Conor, as collateral for the full and faithful performance by Distributor of all of its
obligations under this Agreement, an irrevocable and unconditional negotiable letter of credit (the “Letter of Credit”) in the amount of the purchase order (the “LC Amount”), payable at sight. Such Letter of Credit shall
be issued by a solvent nationally recognized United States or European bank or financial institution with a long term debt rating of BBB or higher, (as rated by Standard & Poor’s) or Baa or higher (as rated by Moody’s Investors
Service) that has a branch office in Dublin, Ireland, from which Conor may draw on such Letter of Credit. The Letter of Credit shall (i) remain valid and subject to the terms of this Section 2(i) for the term of the Agreement, and if the
Letter of Credit is replaced, renewed, or extended during the term of this Agreement, Distributor shall deliver a new Letter of Credit or certificate of renewal or extension to Conor at least thirty (30) days prior to the expiration of the
expiring Letter of Credit, without any action whatsoever on the part of Conor; (ii) be subject to the Uniform Customs and Practices for Documentary Credits, ICC Publication No. 500, (iii) be fully assignable by Conor; and
(iv) permit partial draws. In addition to the foregoing, the form and terms of the Letter of Credit (and the bank issuing the same) shall be acceptable to Conor, in Conor’s sole discretion, and shall provide, among other things, that:
(A) such Letter of Credit shall be irrevocable, unconditional, and payable at sight; (B) Conor, or its then managing agent, shall have the right to draw down an amount up to the face amount of the Letter of Credit upon the presentation to
the issuing bank of Conor’s statement that such amount is due to Conor under the terms and conditions of this Agreement, it being understood that such statement shall be signed by any member of the senior management of Conor and; (C) the
Letter of Credit will be honored by the issuing bank without inquiry as to the accuracy thereof and regardless of whether the Distributor disputes the content of such statement. 
 (j) Interest. All amounts due and owing to Conor hereunder but not paid by Distributor on the due date thereof shall bear interest
(in euros) at the rate of the lesser of: (i) [ * ] per annum above the then-current EURIBOR (European Interbank Offering Rate); and (ii) the maximum lawful interest rate permitted under applicable law. Such interest shall accrue on
the balance of unpaid amounts from time to time outstanding from the date on which portions of such amounts become due and owing until payment thereof in full. 
  



	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 4.









 (k) Purchase order discrepancy. In the event of any discrepancy between any
purchase order accepted by Conor and this Agreement, the terms of this Agreement shall govern. 
 (l) Principle ordering
terms. The Product shall be purchased and sold hereunder on the terms and conditions specified in Conor’s principle ordering terms, as set forth in Exhibit B. Conor shall have the right to modify such terms and conditions, on at least
thirty (30) days’ prior written notice to Distributor. In the event of any discrepancy between such terms and conditions and this Agreement, the terms of this Agreement shall govern. 
 (m) Fees. Distributor shall pay any and all fees, costs and expenses related to obtaining any required licenses, permits or
approvals in the countries of the Territory, including any fees, costs and expenses related to or derived from conducting clinical trials, studies or registries, provided, however, Conor agrees to pay up to a total of [ * ] euros for fees,
costs and expenses related to or derived from conducting clinical trials, studies or registries. 
 (n) Sale or import
without regulatory approval. Conor shall not be responsible for any sale or import of the Product into any countries or regions in which the Product has not received relevant national or supranational regulatory approvals that are legally
required by applicable laws of such country or region. Distributor hereby agrees to indemnify and hold Conor harmless from any damage, costs or liabilities (including reasonable attorneys’ fees) arising out of any claims, demands, suits, or
actions, to the extent arising or resulting from any sale or import into a certain country or region by Distributor without the necessary regulatory approval. 
 3. OTHER OBLIGATIONS OF DISTRIBUTOR. 
 (a) Facilities and resources. Distributor shall employ competent and experienced service personnel, provide appropriate facilities and resources so as to render prompt and adequate service to the users of the
Product in the Territory, and so as to comply with all of Distributor’s obligations under this Agreement. Distributor shall provide adequate and appropriate training to its staff concerning the Product. 
 (b) Promotional Materials. Distributor shall use sales and technical literature as well as promotional artwork and training
materials provided by Conor. Distributor may alter such materials or develop any other materials in connection with the marketing and distribution of the Product (including but not limited to product brochures and sales aids), subject to
Conor’s review and written approval prior to any use of such materials. Conor shall retain all right, title and interest in and to such materials. 
 (c) Customer Service. Distributor shall provide customer service (including, but not limited to, taking orders, responding to customer inquiries, fulfilling requests for quotes on Product pricing, and
forwarding Product complaints to Conor as legally required) on a timely basis and shall provide such assistance and information to customers as is reasonably requested by Conor. 
  



	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 5.









 (d) No debarred or disqualified persons. Distributor warrants that it shall not
employ, contract with, or retain any person directly or indirectly to perform services under this Agreement if such person is (i) debarred by either the U.S. Food and Drug Administration under 21 U.S.C. § 335(a) or any equivalent law or
regulation in the Territory, or (ii) disqualified as described in 21 C.F.R. § 812.119, or any equivalent law or regulation in the Territory. In the event that Distributor becomes aware of the debarment or disqualification of any person
providing services to Distributor which relate to services being provided under this Agreement, Distributor agrees to notify Conor immediately. 
 (e) Translations. Distributor shall translate, at its own expense, all user and technical manuals, and advertising and marketing information into the languages of its customers and provide Conor with advance
copies of all such materials for approval by Conor. Conor shall own such translations and related intellectual property rights, but Distributor has a non-exclusive right to use such translations during the term of this Agreement in connection with
its activities pursuant to this Agreement. 
 4. CONOR’S OBLIGATIONS. 
 (a) Assistance. Conor shall provide Distributor with such marketing and technical assistance and free Product samples as Conor may
in its discretion consider necessary to assist with the promotion of the Product. 
 (b) Training. Conor shall provide
product launch training to Distributor’s personnel in connection with the marketing, sale, maintenance and support of the Product. 
 (c) Maintenance. Conor shall designate maintenance and support personnel to assist Distributor’s support personnel in providing maintenance and support services. 
 5. RELATIONSHIP OF THE PARTIES. 
 (a) Independent contractor. Distributor shall be considered to be an independent contractor. The relationship shall not be
construed to be that of employer and employee, nor to constitute a partnership, joint venture or agency of any kind. 
 (b)
Expenses. Distributor agrees to pay, and shall solely bear, all of its incurred expenses in connection with this Agreement, including without limitation all travel, lodging and entertainment expenses. 
 (c) Distributor not to enter contracts that bind Conor. Distributor shall have no right to enter into any contracts or commitments
in the name of, or on behalf of, Conor, or to bind Conor in any respect -whatsoever. 
 (d) No obligations to third
parties. In addition, Distributor shall not obligate or purport to obligate Conor by issuing or making any affirmations, representations, warranties or guaranties with respect to the Product to any third party. 
  



	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 6.









 6. BEST EFFORTS. 
 (a) Distributor to use best efforts. Distributor agrees, for the term of and subject to the provisions of the term of this
Agreement, to use its best efforts to promote and market the Product to the maximum number of customers in the Territory. Distributor and Conor shall mutually agree in writing on the sales promotion activities and performance objectives to be met by
Distributor for Conor’s fiscal year. Distributor shall provide Conor with an annual analysis of the market, including market size, market share data, and competitive activities. Such information shall be provided to enable Conor in developing
the global marketing and business plans for the mutual advantage of Distributor and Conor. Upon signing this Agreement, Distributor and Conor will jointly establish Distributor’s performance objectives for Conor’s fiscal year. The
establishment of performance objectives will be repeated annually. The established performance objectives will become a part of this Agreement, and will be attached hereto as Exhibit C. 
 (b) Failure to use best efforts. Failure to meet any minimum established performance objectives shall constitute a material breach
of this Agreement for the purposes of Article 14. 
 7. REPORTING. 
 (a) Customer reports. Distributor shall provide Conor with written quarterly reports, which shall include customer call reports,
business trends, sales forecasts for the significant customers in the Territory, market forecasts and other reports requested by Conor. 
 (b) Adverse Event Reporting. Distributor shall notify Conor immediately of (i) all adverse comments or complaints by Distributor’s customers regarding the Product, including comments regarding the
Product’s quality, stability, contamination, potency, condition, packaging, or any other attributes or defects, and (ii) all adverse events and adverse reactions that may be attributable to a customer’s use of the Product, whether or
not Distributor can confirm that the event is actually associated with the Product, and whether or not Distributor can confirm that the event was due to improper dosing or other negligence on the part of the physician or patient. Distributor shall
provide Conor with information regarding the reporting requirements in the Territory. 
 (c) Alleged Defects. In the
event of an actual or alleged malfunction or defect of a Product, Distributor or its representatives or agents shall not make any statement as to the cause, prior to receiving Conor’s written analysis of such malfunction or defect, and shall
thereafter make no statements contrary to or inconsistent with the results of such analysis. 
 (d) Product Recall. If
either Party believes that a recall of any Product in the Territory is desirable or required by law in the Territory or elsewhere, it shall immediately notify the other Party. The Parties shall then discuss reasonably and in good faith whether such
recall is appropriate or required and the manner in which such recall should be handled. 
 (e) Remedial Actions. It is
Conor’s exclusive right to issue recalls, safety alerts, advisory notices or similar remedial actions with respect to the Product. In the event of such remedial action, Distributor will support and fully cooperate with Conor to comply with
applicable laws and regulations, and Distributor will notify its customers and, upon Conor’s request, retrieve the identified Product. 
  



	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 7.









 8. FIELD ASSISTANCE. Conor shall provide, in its discretion,
appropriate field technical assistance to Distributor and Distributor’s customers. 
 9. TRADEMARKS,
SERVICE MARKS AND OTHER INTELLECTUAL PROPERTY. 
 (a) Intellectual Property. Distributor may use Conor’s trade names, trademarks and service marks that are designated by Conor for each Product (the “Conor Intellectual Property”) on a
non-exclusive basis in the Territory, only for the duration of this Agreement and solely in connection with selling, marketing and distributing the Product in accordance with this Agreement. Distributor shall, upon Conor’s request, cooperate
with Conor in any action necessary or desirable to register with the appropriate governmental agencies any Conor trademark used or proposed to be used hereunder, and to protect any Conor trademark proposed to be used. Distributor shall not at any
time do or permit any act to be done which may in any way impair the rights of Conor in the Conor Intellectual Property or the value of the Conor Intellectual Property. 
 (b) Quality Control. In order to comply with Conor’s quality control standards, Distributor shall: (i) use the Conor
Intellectual Property in compliance with all relevant laws and regulations; (ii) accord Conor the right to inspect during normal business hours, without prior advance notice, Distributor’s facilities used in connection with efforts to
store or sell the Product in order to confirm that Distributor’s use of such Conor Intellectual Property is in compliance with this provision; and (iii) not modify any of the Conor Intellectual Property in any way and not use any of the
Conor Intellectual Property on or in connection with any goods or services other than the Product. 
 (c) Inventions.
Any inventions made, developed, conceived, or reduced to practice by Distributor that relate to the Product (including any associated delivery systems), and any intellectual property relating thereto, shall be owned solely by Conor. Distributor
hereby assigns and transfers to Conor all right, title, and interest in and to such inventions and related intellectual property and agrees to take all further acts reasonably required to evidence such assignment and transfer to Conor, all at
Conor’s expense. Conor hereby grants to Distributor a nonexclusive, royalty-free, nontransferable, nonsublicenseable license to such inventions made by Distributor for uses other than in the Product and associated delivery systems. 

(d) Notice of Intellectual Property Infringement. Distributor shall promptly notify Conor in writing of any patent or copyright
infringement or unauthorized use of Conor trade secrets or trademarks in the Territory of which Distributor becomes aware. Conor shall have the exclusive right in its sole discretion to institute any proceedings against such third party in its name
and on its behalf. Distributor shall cooperate fully with Conor in any legal action taken by Conor against such third parties, provided that Conor shall pay all expenses of such action and all damages relating to damage suffered personally by Conor
which may be awarded or agreed upon in settlement of such action shall accrue to Conor. 
  



	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 8.









 10. COVENANT NOT TO COMPETE. During
the term of this Agreement, Distributor shall not market directly or indirectly in the Territory any drug-eluting stent products. In the event the Distributor breaches the terms of this Section 10, Distributor’s appointment as exclusive
distributor of the Product under Section 1(a) will convert to an appointment as a non-exclusive distributor of the Product, which remedy shall not be exclusive of, and shall be in addition to, any other remedies available to Conor at law or in
equity with respect to such breach. 
 11. LIMITED WARRANTY. 
 (a) Representations by Conor. As to all components of the Product manufactured by Conor, Conor warrants that, at the time of
shipment, the Product supplied by Conor hereunder (i) shall meet the Product specifications agreed to in writing by the parties, (ii) shall not be adulterated or misbranded within the meaning of the U.S. Food, Drug and Cosmetic Act (the
“Act”) or other applicable laws that are equivalent thereto in the Territory, and in which the definitions of adulteration and misbranding are substantially the same as those contained in the Act, (iii) shall be manufactured in
accordance with Good Manufacturing Practices as defined in the Act and the World Health Organization Guidelines; provided, however, that Conor shall not be liable for any of the foregoing with respect to any product labeling or package inserts to be
provided or used by Distributor, or any translation thereof, or for any noncompliance with the foregoing due to the handling or packaging of the Product by Distributor. 
 (b) Limitations. Under no circumstances shall the warranties set forth in Section 11(a) apply to any Product which has been
used with unapproved components or to any Product which has been customized or modified, damaged, reused, or misused. In the event that the warranties set forth in Section 11(a) are breached and Conor is responsible for such breach, Conor will
replace the defective product at no cost to Distributor. THE PROVISIONS OF THE FOREGOING WARRANTIES ARE IN LIEU OF ANY OTHER WARRANTY, WHETHER EXPRESS OR IMPLIED, WRITTEN OR ORAL (INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE). CONOR’S LIABILITY ARISING OUT OF THE MANUFACTURE, SALE OR SUPPLY OF THE PRODUCT UNDER THIS AGREEMENT OR THE USE OR DISPOSITION OF THE PRODUCT BY DISTRIBUTOR OR ITS CUSTOMER, WHETHER BASED UPON WARRANTY, CONTRACT, TORT OR OTHERWISE,
SHALL NOT EXCEED THE ACTUAL PURCHASE PRICE PAID BY DISTRIBUTOR FOR THE PRODUCT. IN NO EVENT SHALL CONOR BE LIABLE TO DISTRIBUTOR OR ANY OTHER PERSON OR ENTITY FOR SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT NOT LIMITED TO, LOSS OF
PROFITS, LOSS OF DATA OR LOSS OF USE DAMAGES) ARISING OUT OF THE MANUFACTURE, SALE OR SUPPLY OF THE PRODUCT EVEN IF CONOR HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR LOSSES. 
  



	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 9.









 12. REPRESENTATIONS BY DISTRIBUTOR;
DISTRIBUTOR COVENANTS. 
 (a) Distributor hereby represents and warrants to Conor
that, as of the Effective Date: 
 (i) it is qualified and permitted to enter into this Agreement and that the terms of
this Agreement do not conflict with and are not inconsistent with any other of its contractual obligations; 
 (ii) it
is validly existing and in good standing as a corporation under the laws of India, and has all necessary corporate power to perform its obligations under this Agreement and its financial resources are sufficient to enable it to perform all of its
obligations under this Agreement; 
 (iii) it has not at any time in the past three (3) years been involved, and
is not currently involved, in any litigation or disciplinary action relating to the sale of medical devices before a regulatory authority or under the laws of any country, and to its knowledge no such proceedings are anticipated to commence during
the term of this Agreement; 
 (iv) it has sufficient personnel and capacity to perform its obligations under this
Agreement; and 
 (v) it owns or controls sufficient rights for it to perform its obligations under this Agreement.

 (b) Distributor hereby covenants that Distributor (a) shall store the Product in accordance with the storage
specifications that Conor will provide in writing, and in accordance with all applicable laws, rules and regulations in the Territory, (b) shall distribute and ship the Product within the Territory in accordance with Conor’s packaging,
shipping and distribution specifications for the Product that Conor will provide in writing, and in accordance with all laws, rules and regulations in the Territory, (c) shall not sell any Product with an expired shelf life, and shall dispose
of any such expired Product in the manner required by Conor, and in accordance with all laws, rules and regulations in the Territory, (d) shall not adulterate or misbrand the Product, or engage in any activity that could or does render the
Product adulterated or misbranded, and (e) shall maintain all necessary records for compliance with all laws, rules and regulations in the Territory. 
 13. INDEMNIFICATION IN FAVOR OF CONOR. 
 (a) Indemnification. Distributor shall indemnify, protect and save Conor, its Affiliates (as defined below) and all officers, directors, employees and agents thereof (hereinafter referred to as
“Indemnitees”) harmless from all claims, demands, suits or actions (including attorneys’ fees incurred in connection therewith) which may be asserted against Conor for any kind of damages, including without limitation damage or
injury to property or persons and incidental and consequential damages, which may be sustained by any third party or any of the Indemnitees arising out of or incident to the conduct of Distributor’s operations under this Agreement. For the
purpose of this Agreement, “Affiliate” shall mean, with respect to a party, any company, natural person, partnership or 

  



	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 10.









 
other business entity that controls, is controlled by, or is under common control with such party, where the term “controls” denotes the ownership,
directly or indirectly, of more than fifty percent (50%) of the voting securities or other ownership interest of an entity, or the possession, directly or indirectly, of the power to direct the management or policies of an entity, whether
through the ownership of voting securities, by contract, or otherwise (with correlative definitions for the terms “controlled by” and “common control”). 
 (b) Insurance. During the term of this Agreement and for four (4) years thereafter, Distributor shall maintain an insurance
policy issued by a reputable insurance company, naming Conor as an additional insured, which policy shall insure against any and all claims, liabilities, costs or expenses resulting from or caused by (or claimed to be resulting from or caused by)
any use or operation of any products sold by Distributor in the amount of at least [ * ] euros per claim, and [ * ] euros for claims in the aggregate. 
 14. TERMINATION. 
 (a) Term. The term of this Agreement shall
begin on April 1, 2006 (the “Effective Date”) and shall terminate, unless terminated earlier pursuant to the terms of this Section, on December 31, 2008 (the “Term”). The Term shall be renewable for
additional one (1) year terms on the mutual written agreement of the Parties. Approximately three (3) months prior to the end of the Term, the parties will discuss the possible extension or renewal of this Agreement, which will be based on
a mutually acceptable performance objective. 
 (b) Termination. Conor may terminate this Agreement at any time upon
ninety (90) days written notice to Distributor. 
 (c) Termination for material breach. Upon the occurrence of a
material breach or default as to any obligation hereunder by either party and the failure of the breaching party to cure such material breach or default within thirty (30) days after receiving written notice thereof from the non-breaching
party, this Agreement may be terminated by the non-breaching party by giving written notice of termination to the breaching party, such termination being immediately effective upon the giving of such notice of termination. Material breach includes,
but is not limited to the following: (i) breach by Distributor of the provisions set forth in Article 1 above; (ii) impairment by Distributor of Conor’s rights in the Conor Intellectual Property, in violation of Article 9 above;
(iii) breach by Distributor of the Foreign Corrupt Practices Act; (iv) failure of Distributor to make any payments timely and in accordance with this Agreement; (v) failure to establish and maintain clinical specialists and a sales
organization to adequately and effectively sell the Product within the Territory; (vi) failure to use best efforts or order minimum quantities in accordance with Section 6(a) and Exhibit C; (vii) engaging in any act that is
detrimental to Conor, the Product, or Conor’s reputation; or (viii) any breach of any covenant, representation or warranty in this Agreement, including but not limited to Sections 2(e), 3(a), 5(b), 5(d) and Article 12. 
 (d) Change of Control of Distributor. In the event of a Change of Control of the Distributor, Conor may terminate this Agreement by
giving written notice of termination to Distributor, such termination being immediately effective upon the giving of such notice of termination. 
  



	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 11.









 (e) Bankruptcy. Upon the filing of a petition in bankruptcy, insolvency or
reorganization against or by either party, or either party becoming subject to a composition for creditors, whether by law or agreement, or either party going into receivership or otherwise becoming insolvent (the “Insolvent
Party”), this Agreement may be terminated by the other party by giving written notice of termination to the Insolvent Party, such termination immediately effective upon the giving of such notice of termination. 
 (f) No compensation. In the event of a termination pursuant to any of subsections (b), (c), (d), or (e) above or upon
expiration of this Agreement pursuant to subsection (a) above, Conor shall not have any obligation to Distributor, or to any employee of Distributor, for compensation or for damages of any kind, whether on account of the loss by Distributor or
such employee of present or prospective sales, investments, compensation or goodwill. Distributor, for itself and on behalf of each of its employees, hereby waives any rights which may be granted to it or them under the laws and regulations of the
Territory or otherwise which are not granted to it or them by this Agreement. Distributor hereby indemnifies and holds Conor harmless from and against any and all claims, costs, damages and liabilities whatsoever asserted by any employee, agent or
representative of Distributor under any applicable termination, labor, social security or other similar laws or regulations. 
 (g) Payments owed on termination. Termination of this Agreement shall not affect the obligation of Distributor to pay Conor all amounts owing or to become owing as a result of the Product tendered or delivered to Distributor on or
before the date of such termination, as well as interest thereon to the extent any such amounts are paid after the date they became or will become due pursuant to this Agreement. 
 (h) Transfer of Licenses, Permits and Approvals. Upon termination of this Agreement, Distributor shall transfer, if legally able to
do so, to Conor any and all licenses, permits and approvals that Distributor obtained in accordance with Section 30. 
 (i) Surviving provisions. Notwithstanding anything else in this Agreement to the contrary, the parties agree that Sections 2(e), 2(f), 3(b) and Articles 7 (as to the Product sold during the term), 9, 11(b), 13, 14, 15, 19, 20, 22,
24, 26, 27, 30, and 31 shall survive the termination or expiration of this Agreement, as the case may be, to the extent required thereby for the full observation and performance by any or all of the parties hereto. 
 15. SELL-OFF PERIOD; REPURCHASE OF INVENTORY.

 (a) Sell-Off Period. Upon termination or expiration of this Agreement other than by Conor pursuant to
Section 14(c) or Section 14(d), Distributor shall have the right to sell off its remaining inventory of the Product on a non-exclusive basis for four (4) months after such termination or expiration or for so long as such inventory
exists, whichever is shorter; provided, however, that Distributor shall comply with all terms and conditions of this Agreement, including those that restrict reselling activities, in effect immediately prior to termination or expiration.
Distributor’s rights under this Section 15(a) are expressly subject to Conor’s option to repurchase Distributor’s inventory of the Product, as set forth in Section 15(b). 
  



	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 12.









 (b) Option to repurchase. Upon either termination or expiration of this Agreement,
as the case may be, Conor shall have the option to repurchase Distributor’s inventory of the Product, which option must be exercised in writing within thirty (30) days after such termination or expiration. If Conor so exercises such
option, Conor shall repurchase Distributor’s inventory of Products that are saleable and in the original packages and unaltered from their original form and design, subject to Conor’s inspection, test, and acceptance. 
 (c) Repurchase price. Any such repurchase of Distributor’s inventory of Products shall be at [ * ]. Repurchased
inventory shall be shipped by Distributor freight prepaid, according to Conor’s instructions. Conor shall pay Distributor for such repurchased Products within thirty (30) days after Conor receives those Products in one of its facilities.

 16. PUBLICITY. Distributor agrees that any publicity or advertising which shall be released by it in which Conor is
identified in connection with the Products shall be in accordance with the terms of this Agreement and with any information or data which Conor has furnished in connection with this Agreement. Copies of all such publicity and advertising shall be
forwarded promptly to Conor. 
 17. MODIFICATION. No modification or change may be made in this Agreement except by
written instrument duly signed by Distributor and by a duly authorized representative of Conor. 
 18. ASSIGNMENT.
Distributor may not assign all or any part of its rights and obligations under this Agreement to anyone without the prior written consent of the Conor. Conor may assign its rights and obligations under this Agreement to (a) any of its
Affiliates, (b) any person or entity to whom Conor licenses or otherwise transfers the right to manufacture Product (subject to appropriate written notice to Distributor to facilitate any necessary change in Government Approvals), or
(c) any person or entity with which Conor is merged or by which it is acquired or which purchases all or substantially all of its assets; provided that any such assignee agrees to abide and perform all Conor’s obligations and duties under
this Agreement. Conor shall notify Distributor of any such assignment. Any prohibited assignment shall be null and void. 
 19.
NOTICE. All notices given under this Agreement shall be in writing and shall be addressed to the parties at their respective addresses set forth below: 
 IF TO DISTRIBUTOR: 
 INTERVENTIONAL TECHNOLOGIES LIMITED 
 Mumbai, India 201, Steel House, 2nd Floor 24, 
 Mahal Industrial Estate, Mahakali Caves Road, 
 Andheri(E) Mumbai-400 093 India 
 Fax: 001-91-22-26873706 
 Attention: Vali Kasim 
  



	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 13.









 IF TO CONOR: 
 CONOR MEDSYSTEMS IRELAND LIMITED 
 IDA Business and Technology Park, Garrycastle 
 Athlone, County Westmeath, Ireland 
 Fax: +353 (0) 9064 71100 
 Attention: James Hallums 
 Either party may change its address or its telecopy or fax number for purposes of this Agreement by giving the other party written notice of its new address or telecopy
number. Any such notice if given or made by registered or recorded delivery international air mail letter shall be deemed to have been received on the earlier of the date actually received and the date fifteen (15) calendar days after the same
was posted (and in providing such it shall be sufficient to prove that the envelope containing the same was properly addressed and posted as aforesaid) and if given or made by telecopy transmission shall be deemed to have been received at the time
of dispatch, unless such date of deemed receipt is not a Business Day, in which case the date of deemed receipt shall be the next such succeeding Business Day. 
 20. WAIVER. None of the conditions or provisions of this Agreement shall be held to have been waived by any act or knowledge on the part of either party, except by an instrument in writing signed
by a duly authorized officer or representative of the parties. Further, the waiver by either party of any right hereunder or the failure to enforce at any time any of the provisions of this Agreement, or any rights with respect thereto, shall not be
deemed to be a waiver of any other rights hereunder or any breach or failure of performance of the other party. 
 21.
VALIDITY. Distributor warrants that this Agreement is lawful and may be performed in accordance with its terms under all laws in force in India and all of the countries comprising the Territory at the time of execution of this
Agreement. Conor and Distributor covenant and warrant that they will each advise the other of any changes in the respective laws of which they become aware which might or will impair the validity of all or any part of this Agreement. 
 22. CONSTRUCTION OF AGREEMENT AND RESOLUTION OF
DISPUTES. This Agreement shall be interpreted in accordance with the commonly understood meaning of the English words and phrases hereof in United Kingdom, and it and performance of the parties hereto shall be construed and
governed according to the laws of the United Kingdom, without regard to conflicts of law principles that would provide for application of the law of a jurisdiction outside of the United Kingdom. The Parties agree that the United Nations Convention
on Contracts for the International Sale of Goods (CISG) does not apply to this Agreement. 
  



	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 14.









 (a) Right to judicial proceedings. Each party shall have the right to institute
judicial proceedings against the other party or anyone acting by, through or under such other party, in order to enforce the instituting party’s rights hereunder through reformation of contract, specific performance, injunction or similar
equitable relief. 
 (b) Jurisdiction. The parties irrevocably submit to the jurisdiction of the state and federal
courts of the United Kingdom; provided, however, that nothing herein shall preclude either party from instituting proceedings against the other party or anyone acting by, through or under the other party in any place which may have jurisdiction for
the purpose of protecting and enforcing such party’s rights either hereunder or pursuant to any other agreements, documents, instruments or otherwise. 
 (c) Service by mail. In the alternative, service of process may be made by postage prepaid registered or recorded delivery air-mail letter transmitted by either party to the other party at the address for
notices set forth above for such other party with a duplicate copy sent by postage prepaid registered or recorded delivery air mail letter to the agent appointed by such other party hereunder. 
 (d) Waiver of objection. Each party hereby irrevocably waives any objection which it may now or hereafter have to the laying of
venue of any suit, action or proceeding relating to this Agreement in United Kingdom and further irrevocably waives any claim that the United Kingdom is not a convenient forum for any such suit, action or proceeding. 
 23. CONOR OFFICE IN THE TERRITORY. Conor may from time to time maintain
an office at one or more locations in or near the Territory. Personnel associated with such office or offices shall be authorized to and may, from time to time, act on behalf of Conor and shall be entitled to exercise all of the rights of Conor
under this Agreement. Such personnel shall be entitled to all information with respect to all matters relevant to Distributor’s performance under the Agreement, and Distributor shall at all times cooperate with such personnel with respect to
all such matters. 
 24. CONFIDENTIALITY MAINTAINED. 
 (a) Proprietary Information. Distributor agrees that Conor has a proprietary interest in any information provided to Distributor by
Conor, whether in connection with this Agreement or otherwise, whether in written or oral form, which is (i) a trade secret, confidential or proprietary information, and (ii) not publicly known (the “Proprietary
Information”). Distributor shall disclose the Proprietary Information only to those of its agents and employees to whom it is necessary in order to carry out their duties properly as limited by the terms and conditions hereof. Both during
and after the term of this Agreement, all disclosures by Distributor to its agents and employees shall be held in strict confidence by such agents and employees. During and after the term of this Agreement, Distributor, its agents and employees
shall not use the Proprietary Information for any purpose other than in connection with Distributor’s sale and distribution of the Products in the Territory pursuant to this Agreement. Distributor shall, at its expense, return to Conor the
Proprietary Information as soon as practicable after the termination or expiration of this 

  



	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 15.









 
Agreement. All such Proprietary Information shall remain the exclusive property of Conor during the term of this Agreement and thereafter. This
Section 24(a) shall also apply to any consultants or subcontractors that Distributor may engage in connection with its obligations under this Agreement. 
 (b) Permitted disclosure. Notwithstanding anything contained in this Agreement to the contrary, Distributor shall not be liable for
a disclosure of the Proprietary Information of Conor, solely to the extent that the information so disclosed: (i) was in the public domain at the time of disclosure without breach of this Agreement; or (ii) was known to or contained in the
records of Distributor from a source other than Conor at the time of disclosure by Conor to Distributor and can be so demonstrated by competent written records; or (iii) was independently developed and is so demonstrated promptly upon receipt
of the documentation and technology by Distributor; or (iv) becomes known to Distributor, without any restrictions on further disclosure, from a source other than Conor without breach of this Agreement by Distributor and can be so demonstrated
by competent written records. 
 25. ENTIRE AGREEMENT. This Agreement, including all Exhibits and
appendices hereto, supersedes, terminates and cancels any previous agreements or understandings, including the International Distribution Agreement between Conor and Distributor, dated July 1, 2004 (except for the surviving provisions of that
agreement which shall continue to survive), whether oral, written or implied, heretofore in effect and sets forth the entire agreement between Conor and Distributor with respect to the subject matter hereof. 
 26. NO RIGHTS BY IMPLICATION. No rights or licenses with respect to the Products or the
Conor Intellectual Property are granted or deemed granted hereunder or in connection herewith, other than those rights expressly granted in this Agreement. 
 27. RESPONSIBILITY FOR TAXES. Taxes, whether in India or any other country, now or hereafter imposed with respect to the transactions contemplated hereunder (with
the exception of income taxes or other taxes imposed upon Conor and measured by the gross or net income of Conor) shall be the responsibility of Distributor, and if paid or required to be paid by Conor, the amount thereof shall be added to and
become a part of the amounts payable by Distributor hereunder. 
 28. MODIFICATION OF
PRODUCTS. Distributor may not customize, modify or have customized or modified any Product unless it obtains the prior written consent of Conor, which consent may be withheld in the sole discretion of Conor. Any unauthorized
customizing or modification of any Product by Distributor or any third party shall relieve Conor from any obligation it would otherwise have had with respect to such Product under the warranties described herein. 
 29. FORCE MAJEURE. 
 (a) No liability for damages. Neither Conor nor Distributor shall be liable in damages, or shall be subject to termination of this Agreement by the other party, for any delay or default in performing any
obligation hereunder if that delay or default is due to any 

  



	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 16.









 
cause beyond the reasonable control and without fault or negligence of that party; provided that, in order to excuse its delay or default hereunder, a party
shall notify the other of the occurrence or the cause, specifying the nature and particulars thereof and the expected duration thereof; and provided, further, that within fifteen (15) calendar days after the termination of such occurrence or
cause, such party shall give notice to the other party specifying the date of termination thereof. All obligations of both parties shall return to being in full force and effect upon the termination of such occurrence or cause (including without
limitation any payments which became due and payable hereunder prior to the termination of such occurrence or cause). 
 (b) Cause beyond reasonable control. For the purposes of this Section, a “cause beyond the reasonable control” of a party shall include, without limiting the generality of the phrase, any act of God, act of any government
or other authority or statutory undertaking, industrial dispute, fire, explosion, accident, power failure, flood, riot or war (declared or undeclared). 
 30. COMPLIANCE WITH LAWS. Each of Distributor and Conor covenants that all of its activities under or pursuant to this Agreement shall comply with all applicable
laws, rules and regulations. In particular, but without limitation, Distributor shall assist Conor in obtaining all licenses, permits and approvals which are necessary or advisable for sales of the Products in the Territory and for the performance
of its duties hereunder, unless laws or regulations of a country in the Territory require that the Distributor obtain such licenses, permits or approvals; in that event, Distributor shall obtain the license, permit or approval. For clarity, all
licenses, permits or approvals shall be held by or in the name of Conor unless laws or regulations of a country in the Territory require that the Distributor obtain such licenses, permits or approvals, in that event, Distributor shall obtain the
licenses, permit or approval. 
 31. SEVERABILITY. If any provision of this Agreement is declared invalid or
unenforceable by a court having competent jurisdiction, it is mutually agreed that this Agreement shall endure except for the part declared invalid or unenforceable by order of such court. The parties shall consult and use their best efforts to
agree upon a valid and enforceable provision which shall be a reasonable substitute for such invalid or unenforceable provision in light of the intent of this Agreement. 
 32. COUNTERPARTS. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 33. PERFORMANCE BY AFFILIATES. The Parties recognize that Conor may perform some or all
of its obligations, or exercise some of all of its rights, under this Agreement through one or more of its Affiliates. Any reference to Conor in this Agreement shall be deemed to include any such Affiliates of Conor so engaged by Conor as it deems
appropriate in light of the particular facts and circumstances. 
 {SIGNATURE PAGE FOLLOWS}

  



	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 17.









 IN WITNESS WHEREOF, the parties
hereto have signed this Agreement. 
  

							
	DISTRIBUTOR:	 	INTERNATIONAL TECHNOLOGIES LIMITED
				
		 	By:	 	/s/ V. M. Kasim	 	18/5/06
		 	Name:	 	Mr. V. M. Kasim, M.D.	 	
		 	Title:	 	M.D. & Chairman	 	
			
	CONOR:	 	CONOR MEDSYSTEMS IRELAND LTD.	 	
				
		 	By:	 	/s/ Heather Turner	 	
		 	Name:	 	Heather Turner	 	
		 	Title:	 	Director	 	
		 		 	Hamilton, Bermuda	 	4/27/06

  



	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 18.









 EXHIBIT A 
 PRODUCT CLASS AND PRICE LIST 
  

			
	 PRODUCT
	  	PRICE (EUROS)
	 Conor cobalt chrome stent with paclitaxel
	  	[ * ]

 Company may increase Product price no more than [ * ] in any calendar
year. 
 The Product price is established in conjunction with Section 2 this agreement. 
  



	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 19.









 EXHIBIT B 
 PRINCIPLE ORDERING TERMS 
 1.
V.A.T., Taxes and Duties. All prices quote exclude V.A.T., state, federal and governmental taxes and duties, and Interventional Technologies Limited (BUYER) will be liable for such taxes if applicable. 
 2. Delivery charges. All the prices, unless otherwise agreed between the parties, do not include delivery charges (prices are considered FCA
—Incoterms 2000 Conor’s Plants). RI BUYER shall specify the carrier on each purchase order. 
 3. Purchase Orders. The BUYER
shall submit purchase orders for the Products in writing which, at minimum, shall set forth: 
 (a) an identification
of the Products ordered (Conor’s catalog number); 
 (b) quantity per each product; 
 (c) requested delivery date 
 (d) any special shipping and packaging instructions; and 
 (e) shipping
address. 
 4. Acceptance and Confirmation of Orders. On receipt of an order, a detailed proforma invoice (Order Confirmation) is faxed
to the BUYER as an order acknowledgement. 
 5. Modifications of Orders. No accepted and confirmed purchase orders shall be modified or
cancelled except upon the written agreement of both parties. 
 6. Quantities Required. Products to be purchased by the BUYER must be
at least [ * ] per catalog number in order to facilitate the storage and shipping conditions of the Products. 
 7. Complete
Orders. Purchase orders are considered shipped complete when the quantity invoiced is the same as the ordered quantity. 
  



	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 20.









 EXHIBIT C 
 MINIMUM QUARTERLY PURCHASE ORDERS 
 (IN UNITS) 
 AGREEMENT YEAR 2006

  

							
	 Product
	  	Q2	 	Q3	 	Q4
	 Conor cobalt chrome stent with paclitaxel
	  	[ * ]	 	[ * ]	 	[ * ]

 AGREEMENT YEAR 2007 
  

									
	 Product
	  	Q1	 	Q2	 	Q3	 	Q4
	 Conor cobalt chromium stent with paclitaxel
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]

 AGREEMENT YEAR 2008 
  

									
	 Product
	  	Q1	 	Q2	 	Q3	 	Q4
	 Conor cobalt chromium stent with paclitaxel
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]

  



	[ * ] =	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

 21.